Sino Biopharm 1177

Re: Sino Biopharma 1177

Postby winston » Wed May 13, 2015 6:37 am

not vested

SINO BIOPHARM(01177.HK) 1Q net profit up 19.79%; quarterly div. 1.5 cents

SINO BIOPHARM (01177.HK) 0.000 (0.000%) Short selling $10.50M; Ratio 6.568% announced the first quarter results for 31 March ended 2015.

Net profit added 19.79% yearly to HK$400 million.

EPS equaled HK8.1 cents.

Quarterly dividend of HK1.5 cents was declared, same in the year-ago period.


Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Sino Biopharm 1177

Postby winston » Wed May 13, 2015 1:59 pm

not vested

<Research Report>C Suisse upgrades SINO BIOPHARM(01177.HK) to Outperform with target lifted to $11

Credit Suisse, in its report, stated that SINO BIOPHARM(01177.HK)'s underlying profit for the first quarter gained 20% year-on-year, beating the market projections of 10% to 15%.

That was mainly attributable to strong growth recovery of Runzhong and contributions from new drugs of oncology and respiratory system.

The market expected SINO BIOPHARM's EPS growth in FY2015 to increase 11.6%.

The broker considered the assumption is too conservative.

The rating was upgraded from Neutral to Outperform and the target price was raised to $11 from $7.5.


Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Sino Biopharm 1177

Postby winston » Sat Jan 09, 2016 9:03 pm

not vested

J&J Signs Deal with SINO BIOPHARM (01177.HK) for Hepatitis B Drugs


Johnson & Johnson (J&J) announced that it had reached an agreement with Chia Tai Tianqing Pharmaceutical, a subsidiary of SINO BIOPHARM (01177.HK) -1.330 (-20.060%) Short selling $76.14M; Ratio 6.463% , pursuant to which, the former will have the licensed rights from the latter for drugs to spur the immune system to help fight chronic hepatitis B.

The rights enable J&J to develop, produce and sell the drugs out of China.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Sino Biopharm 1177

Postby winston » Mon Jan 11, 2016 10:53 am

not vested

CHINA CINDA (01359.HK) Places H Shares to SINO BIOPHARM (01177.HK) to Raise Over $5.8B

CHINA CINDA (01359.HK) announced that it had entered into an agreement with SINO BIOPHARM (01177.HK) on 7 January to place 1.908 billion new H shares, representing about 4.999% of the enlarged issued share capital of CHINA CINDA, at a subscription price of about $3.05 per share, representing a premium of about 16% over the closing price quoted on the last trading day.

The total consideration of the subscribed shares was about $5.819 billion.

On 7 January, the company had also entered into a strategic cooperation agreement with SINO BIOPHARM, pursuant to which, both parties agreed to utilize their respective resources, expertise and experience to explore business opportunities in a wide range, focusing healthcare and life insurance.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Sino Biopharm 1177

Postby winston » Fri Jul 08, 2016 3:57 pm

May 24, 2016

not vested

<Research Report>C Suisse Downgrades SINO BIOPHARM (01177.HK) to Neutral with Target Cut to $5.5

Credit Suisse stated in its report that the results of Chinese national drug price negotiation was released on 20 May.

The ASP of Tenofovir will get reduced from RMB999 to RMB490 per box. After the price cut, the cost of Tenofovir will be similar to Entecavir of SINO BIOPHARM (01177.HK).

The research house believed this will negatively impact Sino Biopharm's sales growth of Entecavir in the long term, although the impact is minimal in 2016 as it takes time for doctors to change their prescription behavior.

Excluding negative RMB depreciation impact of 4.4 ppts, Sino Biopharm's 1Q15 revenue grew by 16%, largely in line with Credit Suisse's expectation.

The research house cut its FY17/18 forecast by 6.3%/9.5% for lower sales growth of hepatitis drugs.

It downgraded the company from Outperform to Neutral with target price trimmed from $7.5 to $5.5.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Sino Biopharm 1177

Postby winston » Fri Jul 08, 2016 3:58 pm

not vested

May 18, 2016

<Result Ann>SINO BIOPHARM 1Q Net Profit Up 31.99% to $528M; Div HK1.5 Cents

SINO BIOPHARM (01177.HK) announced that for the first quarter of 2016, the net profit rose 31.99% yearly to $528 million. The EPS equaled HK7.12 cents; a quarterly dividend of HK1.5 cents was declared.

During the period, the turnover rose 11.61% yearly to $4.168 billion; gross profit rose 12.77% yearly to $3.297 billion.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Sino Biopharm 1177

Postby winston » Mon Aug 29, 2016 1:45 pm

not vested

<Result Ann>SINO BIOPHARM Interim Net Profit Up 8.71% to $1.009B; Interim Div 1.5 Cents

SINO BIOPHARM (01177.HK) announced that for the interim period as of the end of June, the net profit rose 8.71% yearly to $1.009 billion.

The EPS equaled 13.61 cents; an interim dividend of 1.5 cents was declared.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Sino Biopharm 1177

Postby winston » Mon May 06, 2019 12:02 pm

not vested

SINO BIOPHARM(1177)

Analysis:

The Group's business encompasses a fully integrated chain which spans from R&D to manufacture and sales of pharmaceutical products, covering a vast array of biopharmaceutical, chemical and modernized Chinese medicines.

The Group announced 2018 revenue of RMB 20.89bn (+41% YoY) and net profit of RMB 9.04bn (+317% YoY).

Excluding one-off gains from the acquisition of a 24% stake in Beijing Tide in 2018, adjusted net profit reached RMB 2.84bn (+37% YoY), in line with market consensus.

Sales of oncology drugs reached RMB 3.19bn, occupying 15.3% of total revenue and increasing 99.6% YoY, mainly driven by sales contribution from Fukewei (anlotinib capsule), and it is expected to maintain a rapid growth in 2019.

In 2018, the Group's R&D expenses increased 31% YoY to RMB 2.09bn, R&D expense-to-revenue ratio declined 0.8ppts YoY to 10.0%.

The number of products under development is 497, and 18 drugs were approved for production in 2018.

Considering its heavy investment in R&D and with continuous genetic and innovative drugs marketed, it will benefit the Group's medium and long term development.

Strategy:
Buy-in Price: $7.50, Target Price: $8.50, Cut Loss Price: $7.10

Source: Phillips
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Sino Biopharm 1177

Postby winston » Thu May 23, 2019 9:16 am

not vested

Sino Biopharmaceutical: Guiding for 15-20% growth

Sino Biopharmaceutical Limited [1177 HK] reported 1Q19 net earnings of RMB856.7m, up 11% YoY.

Gross profit margin improved from 79.7% in 1Q18 and 78.5% in 4Q18 to 80.5% by 1Q19.

Total operating expenses rose 39.8%, which led to a drop in pretax profit margin from 23.3% in 1Q18 to 20.0% in 1Q19.

Research and Development (R&D) cost rose 41.3% to RMB864.6m or 13.9% of revenue.

Management raised 2019 profit guidance to 15-20%.

Pharmaceutical product prices have dropped since the implementation of centralized drug procurement in “4+7” cities.

Controls on the use of adjuvant drugs and antibiotics remained.

Policy uncertainty remains and this is not helped by the current trade war tensions, which could limit price upside.

Our fair value for the stock is HK$8.07. HOLD.

Source: OCBC
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Sino Biopharm 1177

Postby winston » Wed May 29, 2019 1:51 pm

not vested

SINO BIOPHARM(1177)

Analysis:

Sino Biopharmaceutical`s (1177) products comprise a variety of biopharmaceutical and chemical medicines for treating tumours, liver disease, cardio-cerebral diseases, analgesia, respiratory system diseases and orthopeic diseases.

The Group continues to focus on developing specialized medicines where its strength lies so as to build up its brand in specialist therapeutic areas.

For the three months ended 31 March 2019, the Group recorded revenue of RMB6.2 billion, an increase of 33.4% over the same period last year.

Underlying profit attributable to shareholders was RMB976 mill ion, 22.4% higher than that of the same period last year, implying that macro economic uncertainties and the implementation of centralized drug procurement in 4+7 cities by the Chinese government so far had no adverse impact on its operating results. (I do not hold the above stock)

Strategy:
Buy-in Price: $7.75, Target Price: $9.00, Cut Loss Price: $7.20

Source: Phillips
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

PreviousNext

Return to S to Z

Who is online

Users browsing this forum: No registered users and 7 guests